Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

ViroCell manufactured a GMP lentiviral vector for UCL to accelerate research into prevention of relapse in childhood blood cancer UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.

The thymus is a crucial training ground for T-cells, the body's "white knights," where they learn to battle the various diseases they may encounter. Thymic function shrinks to nearly nothing as we age ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...